ChinaBio Today
Contributor since: 2007
Company: ChinaBio LLC
Latest Articles
Week In Review: China Pharmas Announce Deals Worth $1.5 Billion
Week In Review: BeiGene Forges $1.3 Billion Bi-Specific Antibody Deal With Zymeworks
Week In Review: Alphamab Closes $100 Million Series A For Oncology Candidates
Week In Review: CStone Pharma, A Suzhou Oncology Company, Files For Hong Kong IPO
Week In Review: bioMérieux Acquires Majority Stake In China Diagnostics Company For $114 Million
Week In Review: Terns Raises $80 Million For China, Global Development Of Drugs Licensed From Lilly
Week In Review: Innovent Completes $421 Million Hong Kong IPO; Will Start Trading Next Week
Week In Review: Innovent's Hong Kong IPO - Raising $422 Million At $2 Billion Valuation
Week In Review: BioSense Exercises $75 Million Option For China Rights To Neovacs' Lupus Immunotherapy
Week In Review: Shanghai Henlius To File For Hong Kong IPO At Valuation Of Over $1 Billion
Week In Review: Agilent Pays $250 Million To Acquire ACEA And Its Cell Therapy Analyzer
Week In Review: WuXi AppTec Files For $1 Billion+ Hong Kong IPO At $13 Billion Valuation
Week In Review: $1.4 Billion In China Life Science Deals And Financings
Week In Review: Jiangsu Hansoh To Raise Up To $3 Billion In Hong Kong IPO
Week In Review: Nearly $1 Billion In Cross-Border China Biopharma Deals
Week In Review: 3 More China Biopharmas Planning Hong Kong IPOs
Week In Review: Shanghai ChemPartner, A China CRO/CMO, Completes Reverse Merger
Week In Review: Shanghai Junshi Biosciences Files For $500 Million Hong Kong IPO
Week In Review: 2 Hong Kong IPOs - BeiGene And Ascletis - Raise A Combined $1.3 Billion
Week In Review: Long Hill Capital Closes $265 Million Fund For China Healthcare
Week In Review: Acletis Raising $457 Million In Hong Kong IPO At $2 Billion Valuation
Week In Review: Tasly Biopharma Completes Pre-IPO Round At $1.9 Billion Valuation
Week In Review: Suzhou Innovent Files For HK IPO - $500 Million Raise Rumored
Week In Review: CStone Acquires China Rights To Leukemia Drug In $424 Million Deal
Week In Review: CITIC Offers $3.6 Billion To Acquire China Biologic
Week In Review: Mevion Medical Of Boston Closes $150 Million Financing From China Investors
Week In Review: Hua Medicine Approved For $200 Million Hong Kong IPO
Week In Review: Alibaba Transfers Assets To Ali Health In $1.4 Billion Deal
Week In Review: Grail, An Oncology Diagnostics Company, Taps China Investors For $300 Million
Week In Review: Fosun In $2 Billion Bidding War For U.S. Rights To Novartis' Generic Drugs
Week In Review: $3.4 Billion Week For China Life Science Deals
Week In Review: Ping An Good Doctor Plans $1 Billion Hong Kong IPO In Mid-May